BioCentury | Sep 4, 2020
Regulation

A glimpse at FDA’s vaccine panel ahead of October’s COVID-19 meeting

...to the public before Phase III trials conclude. “Fully disagree,” he tweeted, responding to a Forbes...
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

...of £1.4 million ($1.8 million) since 2018 in a program from the lab of Stuart Forbes...
BioCentury | May 18, 2020
Product Development

Preclinical data suggest Oxford vaccine could reduce COVID-19 symptoms, won’t provide herd immunity

...acquired by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in 2012, presented a less rosy perspective, writing in Forbes...
BioCentury | Jul 10, 2019
Clinical News

Michael Becker: a voice with purpose

...cancer. He was prolific, with numerous articles and interviews, notably on CBS This Morning and Forbes...
BioCentury | May 24, 2019
Company News

CFIUS influence may have prompted Momenta's restructuring

...Momenta's decision to slash half of its workforce last year. Steve Dickman first reported in Forbes...
BioCentury | Sep 28, 2018
Company News

Management tracks: Zai, Selecta

...CFO. He was VP of finance at the Flavor Holdings Inc. subsidiary of MacAndrews & Forbes...
BioCentury | May 18, 2018
Financial News

MeiraGTx proposes $86.3M IPO

...technology to switch on and off the expression of transgenes. MeiraGTx's President and CEO Alexandria Forbes...
BioCentury | May 15, 2018
Financial News

MeiraGTx plans IPO

...technology to switch on and off the expression of transgenes. MeiraGTx's President and CEO Alexandria Forbes...
BioCentury | Mar 27, 2018
Distillery Therapeutics

Hepatic

...online March 9, 2018 doi:10.1038/s41467-018-03299-5 CONTACT: Stuart J. Forbes, University of Edinburgh, Edinburgh, U.K. email: stuart.forbes@ed.ac.uk Mark...
BioCentury | Sep 2, 2017
Strategy

Back to School 2017: Breach of contract

...the gaps in innovation,” Leonard Schleifer, CEO of Regeneron Pharmaceuticals Inc. , said at the Forbes...
Items per page:
1 - 10 of 117
BioCentury | Sep 4, 2020
Regulation

A glimpse at FDA’s vaccine panel ahead of October’s COVID-19 meeting

...to the public before Phase III trials conclude. “Fully disagree,” he tweeted, responding to a Forbes...
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

...of £1.4 million ($1.8 million) since 2018 in a program from the lab of Stuart Forbes...
BioCentury | May 18, 2020
Product Development

Preclinical data suggest Oxford vaccine could reduce COVID-19 symptoms, won’t provide herd immunity

...acquired by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in 2012, presented a less rosy perspective, writing in Forbes...
BioCentury | Jul 10, 2019
Clinical News

Michael Becker: a voice with purpose

...cancer. He was prolific, with numerous articles and interviews, notably on CBS This Morning and Forbes...
BioCentury | May 24, 2019
Company News

CFIUS influence may have prompted Momenta's restructuring

...Momenta's decision to slash half of its workforce last year. Steve Dickman first reported in Forbes...
BioCentury | Sep 28, 2018
Company News

Management tracks: Zai, Selecta

...CFO. He was VP of finance at the Flavor Holdings Inc. subsidiary of MacAndrews & Forbes...
BioCentury | May 18, 2018
Financial News

MeiraGTx proposes $86.3M IPO

...technology to switch on and off the expression of transgenes. MeiraGTx's President and CEO Alexandria Forbes...
BioCentury | May 15, 2018
Financial News

MeiraGTx plans IPO

...technology to switch on and off the expression of transgenes. MeiraGTx's President and CEO Alexandria Forbes...
BioCentury | Mar 27, 2018
Distillery Therapeutics

Hepatic

...online March 9, 2018 doi:10.1038/s41467-018-03299-5 CONTACT: Stuart J. Forbes, University of Edinburgh, Edinburgh, U.K. email: stuart.forbes@ed.ac.uk Mark...
BioCentury | Sep 2, 2017
Strategy

Back to School 2017: Breach of contract

...the gaps in innovation,” Leonard Schleifer, CEO of Regeneron Pharmaceuticals Inc. , said at the Forbes...
Items per page:
1 - 10 of 117